ASCO 2011

Erlotinib + Gemcitabine/Oxaliplatin (GEMOX) Improves Progression-Free Survival for Adenocarcinoma of the Biliary Tract

Erlotinib, when added to gemcitabine + oxaliplatin chemotherapy, provided a significant benefit in terms of progression-free survival (PFS) in patients with histologically confirmed adenocarcinoma of the biliary tract, though it did not prolong overall PFS for biliary tract cancer, based on data results presented at the American Society of Clinical Oncology’s 2011 Annual Meeting.

Addition of Sorafenib to Gemcitabine Does Not Improve Survival in Advanced Pancreatic Cancer

Data from the BAYPAN study presented at the American College of Clinical Oncology’s 2011 Annual Meeting did not support the addition of sorafenib to gemcitabine therapy in the treatment of advanced pancreatic cancer (APC), in contrast to an earlier Phase I study that demonstrated that this combination was well tolerated and had activity in APC patients.

Quality of Life Significantly Improved with Erlotinib for NSCLC

Erlotinib improved progression-free survival when compared with gemcitabine + carboplatin as first-line treatment for EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer, according to the results of the OPTIMAL study presented at the American Society of Clinical Oncology’s 2011 Annual Meeting.

Improved Survival with Sorafenib + Chemotherapy in Bevacizumab-Treated Advanced Breast Cancer Patients

The addition of sorafenib to chemotherapy improved progression-free survival in patients with advanced breast cancer who had been previously treated with bevacizumab, according to results of a study in the TIES (Trials to Investigate Efficacy of Sorafenib) program presented at the American Society of Clinical Oncology’s 2011 Annual Meeting.

Initial Phase 2 Results of Crizotinib Show Promise in Advanced ALK-Positive NSCLC

Data from an international, multicenter, open-label, Phase 2 clinical study suggested that crizotinib was safe and well-tolerated with preliminary evidence of improved symptoms and clinically meaningful antitumor activity in patients with pretreated ALK-rearranged metastatic non-small cell lung cancer, investigators reported during the American Society of Clinical Oncology’s 2011 Annual Meeting.

Comparison of Two Intensified Regimens in Advanced Urothelial Cancer: A Prospective, Randomized, Phase 3 Study

Dose dense (DD) gemcitabine/cisplatin therapy was not superior to DD methotrexate/vinblastine/doxorubicin HCl/cisplatin in patients with inoperable or recurrent urothelial cancer; however, the former was better tolerated, results of a Phase 3 randomized trial presented at the American Society of Clinical Oncology’s 2011 Annual Meeting have found.

COMFORT-1: JAK Inhibitor Demonstrates Marked and Sustained Clinical Benefits in Patients with Myelofibrosis

Results of COMFORT-I, a randomized, double-blind, Phase 3 trial of ruxolitinib (INCB18424) demonstrated marked and sustained clinical benefits in spleen size, debilitating symptoms, quality of life (QOL), and an acceptable safety profile relative to placebo in patients with myelofibrosis, according to study results presented at the American Society of Clinical Oncology’s 2011 Annual Meeting.